- Home
- GRNT vs VSTM Comparison
GRNT vs VSTM Comparison
Compare GRNT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.73
Company Overview
Basic Information| Metric | GRNT | VSTM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 470.7M |
| IPO Year | 2022 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GRNT | VSTM |
|---|---|---|
| Price | $5.11 | $5.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $8.00 | ★ $14.50 |
| AVG Volume (30 Days) | 548.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 8.54% | N/A |
| EPS Growth | N/A | ★ 6.87 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $380,030,000.00 | $10,000,000.00 |
| Revenue This Year | $34.25 | $208.96 |
| Revenue Next Year | $9.17 | $269.43 |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | ★ 285.21 |
| 52 Week Low | $4.18 | $4.01 |
| 52 Week High | $6.59 | $11.25 |
Technical Indicators
Market Signals| Indicator | GRNT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 39.92 |
| Support Level | $4.84 | $5.58 |
| Resistance Level | $5.43 | $6.91 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 55.34 | 21.33 |
Price Performance
Historical Comparison GRNT
VSTM
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.